Dentico P, Volpe A, Buongiorno R, Grattagliano I, Altomare E, Tantimonaco G, Scotto G, Sacco R, Schiraldi O
Istituto Policattedra, Università, Bari.
Recenti Prog Med. 1995 Jul-Aug;86(7-8):290-3.
In chronic steatosic liver disease, alcohol or non-alcohol related or HBV, HCV, HDV associated, a reduction in hepatic glutathione and, consequently, in the detoxifying effects of hepatocytes is observed. Intravenous administration of high dose glutathione in patients with chronic steatosic liver disease has shown that glutathione significantly improves the rate of some hepatic tests (bilirubin, GOT, GPT, GT) even several months after treatment interruption. Further confirmation of the efficacy of GSH treatment is provided by the reduction of malondialdehyde, a marker of hepatic cell damage. The optimal results obtained in patients receiving 1800 mg/die/i.v. advocate the use of this high dosage.
在慢性脂肪性肝病中，无论是酒精性或非酒精性的，还是与乙肝病毒（HBV）、丙肝病毒（HCV）、丁肝病毒（HDV）相关的，均可观察到肝脏谷胱甘肽减少，进而肝细胞的解毒作用降低。对慢性脂肪性肝病患者静脉注射高剂量谷胱甘肽的研究表明，即使在治疗中断数月后，谷胱甘肽仍能显著改善一些肝脏检查指标（胆红素、谷草转氨酶、谷丙转氨酶、γ-谷氨酰转肽酶）的水平。肝细胞损伤标志物丙二醛的减少进一步证实了谷胱甘肽治疗的有效性。接受每日1800毫克静脉注射的患者取得了最佳效果，这支持使用这种高剂量治疗。
